Skip to content
POM-V Prescription Required Companion Animal

Cardisan 1.25 mg Chewable Tablets for Dogs

Active ingredient: Pimobendan

Form

Chewable

Species

Dogs

Manufacturer

Alfasan Nederland B.V.

VMD MA No.

36408/5011

What it's used for

For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regur...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Pimobendan

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cardisan 1.25 mg Chewable Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the treatment of canine congestive heart failure originating from dilated
cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation).
Do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical
reasons (e.g. aortic stenosis).

Issued: December 2022
AN: 01816/2021
Do not use in cases of known hypersensitivity to the active substance or to any of
the excipients.
In rare cases a slight positively chronotropic effect (rise in heart rate) and vomiting
can occur. However, these effects are dose-dependent and can be avoided by
reducing the dose.
In rare cases transient diarrhoea, anorexia or lethargy have been observed.
Although a relationship with pimobendan has not been clearly established, in very
rare cases, signs of effects on primary haemostasis (petechiae on mucous
membranes, subcutaneous haemorrhages) may be observed during treatment.
These signs disappear when the treatment is withdrawn. In rare cases, an increase

Issued: December 2022
AN: 01816/2021
in mitral valve regurgitation has been observed during chronic pimobendan treatment
in dogs with mitral valve disease.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
None.

i). Special precautions for use in animals
The blood glucose should be tested regularly during treatment in dogs with existing
diabetes mellitus.
Since pimobendan is metabolised mainly via the liver, it should not be used in dogs
with severe impairment of liver function.
Monitoring of cardiac function and morphology is recommended in animals treated
with pimobendan.
(See also section 4.6).
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of animals.
ii). Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This product may cause tachycardia, orthostatic hypotension, flushing of the face
and headaches.
To avoid accidental ingestion, especially by a child, unused tablet parts should be
placed back into the blister and carton and carefully kept away from children. Part
used tablets should be used at the time of the next dose.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Wash hands after use.
iii). Other precautions
Not applicable.
In pharmacological studies no interaction between the cardiac glycoside strophanthin
and pimobendan was observed. The pimobendan-induced increase in cardiac
contractility is attenuated by calcium antagonists and by β-antagonists.
This veterinary medicinal product does not require any special storage conditions.
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.